STAT+: Biotech veteran Jeremy Levin on why the industry’s future is secure, but American leadership is at risk
In an interview, biotech veteran Jeremy Levin discusses his new book, "Biotech in the Balance," highlighting the industry's potential for growth amid scientific advancements, while expressing concern over the erosion of American leadership due to fractured institutions, political instability, and diminishing public trust in science. He advocates for federal reforms to bolster biotech investment and urges industry leaders to address regulatory challenges impacting drug development.
Biotech veteran Jeremy Levin highlights that while the biotech industry's scientific advancements remain robust, the sector's future is threatened by political upheaval, weakening institutions, and short-term investment strategies. He advocates for federal changes to incentivize biotech investment and stresses the need for pharmaceutical companies to actively address regulatory challenges to maintain industry stability. This insight suggests that professionals in the sector should focus on advocating for policy changes and long-term investment strategies to support sustainable growth.